AGC Biologics will produce chronic gout treatment for Horizon Therapeutics

Prospectively, AGC Biologics' Danish unit will help produce the gout treatment Krystexxa for Horizon Therapeutics.

Photo: Colourbox

Contract development and manufacturing organization (CDMO) AGC Biologics will be producing the drug Krystexxa against chronic gout for US firm Horizon Therapeutics in the future. Production will take place in AGC Biolotics' Danish facilities, the contractor informs.

"We are extremely pleased that Horizon has entrusted us to produce KRYSTEXXA at our Copenhagen facility," says AGC Biologics General Manager, Copenhagen, Andrea Porchia in a prepared comment and adds:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs